Botulinum toxin B - Solstice Neurosciences/US WorldMeds

Drug Profile

Botulinum toxin B - Solstice Neurosciences/US WorldMeds

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Torticollis
  • Phase III Sialorrhoea

Most Recent Events

  • 30 Mar 2018 Botulinum toxin B is no longer licensed to Eisai Co Ltd in European Union, Croatia, Iceland, Liechtenstein, Monaco, Norway, Russia, Switzerland, Turkey
  • 30 Mar 2018 Botulinum toxin B licensed to Sloan Pharma in Europe
  • 01 Jun 2017 US WorldMeds completes the OPTIMYST trial in Sialorrhoea in Belarus, USA and Ukraine (Intraglandular) (NCT02610868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top